Biopharmaceuticals Personnel

 News Release - January 29, 2008

Anika Therapeutics Appoints Andrew J. Carter, Ph.D., as Chief Technology Officer

Distinguished Product Research Executive Brings 25 Years of Experience to Company

WOBURN, Mass.--(HSMN NewsFeed)--Anika Therapeutics, Inc. (NASDAQ:ANIK ) today announced the appointment of Andrew J. Carter, Ph.D., as chief technology officer. Dr. Carter was most recently vice president and general manager at Spine Wave, Inc., a private company focused on developing innovative medical devices for the treatment of spinal disorders. As an integral member of the management team developing Anika’s strategic growth plan, Dr. Carter will lead the Company’s overall research and development efforts.

“Dr. Carter’s expertise in orthopedics, along with his experience in commercializing products and bringing them to market, will be a strategic advantage for Anika,” said Charles H. Sherwood, Ph.D., president and chief executive officer. “He has an outstanding record of accomplishment in both the research and product development arenas. This is an exciting time for the Company and we are delighted to have Dr. Carter on board.”

As vice president and general manager at Spine Wave, Dr. Carter was responsible for the company’s disc repair technologies. He was instrumental in the FDA approval of a pilot study for an injectable nucleus replacement.

Prior to Spine Wave, Inc., from 1982 to 2003, Dr. Carter held a variety of positions with increasing responsibility at Smith & Nephew’s corporate research center in the United Kingdom, including development of their orthopedic tissue engineering program, and with S&N Endoscopy in Massachusetts, USA. From 2000, Dr. Carter led S&N Endoscopy’s implant and tissue resection product development efforts.

Dr. Carter holds his degrees from Queen Mary College, University of London, with a Ph.D. and a B.Sc. both in Polymer Science and Technology. He has 16 patents and published patent applications.

About Anika Therapeutics, Inc.

Headquartered in Woburn, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products include ORTHOVISC®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the ELEVESS™ family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next generation products for joint health and aesthetic dermatology based on the Company’s proprietary, chemically modified HA.

Statements in this press release may be considered “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially. Such factors that could cause actual results to differ materially from any forward-looking statements made by the Company include, among others, the company's research and product development efforts and their relative success, the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, and receive FDA or other regulatory approvals of its products. Further information on factors that could affect Anika’s financial results is included in the Company’s filings with the Securities and Exchange Commission including the company's Annual Report on Form 10-K for the year ended December 31, 2006, and its Quarterly Report on Form 10-Q for the quarters ended March 31, June 30 and September 30, 2007 and Current Reports on Form 8-K, as well as those described in the company's other press releases and SEC filings.

Source: Anika Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.